BioNTech SE

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioNTech reports robust 2022 earnings, eyes growth in oncology and infectious diseases

BioNTech's strong financial performance in 2022 sets the stage for continued growth in 2023, with a focus on expanding its vaccine portfolio, advancing oncology programs, and navigating the evolving landscape of COVID-19. The company's strategic priorities align with market demands for infectious disease and oncology solutions, positioning BioNTech for future success and profitability.

BioNTech posts robust Q1 results, eyes growth in vaccines and oncology

BioNTech's Q1 2023 performance reflects strong financial results and promising developments in its vaccine and oncology programs.
While facing challenges such as seasonal trends and data constraints, the company is strategically positioned to leverage opportunities in commercial planning and therapeutic advancements.
With a focus on synergistic partnerships and innovative technologies, BioNTech aims to maintain its competitive edge in the biopharmaceutical industry.
The company's commitment to enhancing existing platforms and exploring new growth avenues underscores its resilience and adaptability in a dynamic market environment.

BioNTech reports mixed Q2 results, focuses on innovation and growth

BioNTech's Q2 2023 performance reflects a mix of strong revenue generation and financial challenges, emphasizing the importance of strategic focus.
The company's strengths lie in its innovative collaborations, pipeline advancements, and preparedness for market demands, despite facing financial losses.
Navigating challenges in financial sustainability, market competition, and stakeholder communication will be crucial for BioNTech's future growth and success.

BioNTech adjusts revenue guidance amidst vaccine demand challenges

BioNTech's Q3 2023 performance reflected revenue challenges from lower COVID-19 vaccine demand and write-downs, prompting revised revenue guidance.
Despite challenges, the company showcased strengths in vaccine development, oncology advancements, and strategic cost management initiatives.
Opportunities lie in shared R&D expenses, long-term growth prospects from combination vaccines, and maintaining financial strength during market transition.

BioNTech reports strong Q4 earnings, eyes diversified product expansion

BioNTech is strategically investing in expanding its product portfolio while navigating uncertainties in COVID-19 vaccine revenues. The company aims to transform into a multiproduct company by 2030, focusing on oncology and infectious diseases.

BioNTech advances oncology pipeline, eyes growth amid financial challenges

BioNTech is making significant strides in its oncology pipeline, aiming for multiple product launches by 2026 and focusing on cancer vaccines and mRNA treatments.
While facing financial losses and short-term profitability challenges, the company remains optimistic about its growth trajectory and revenue potential.
Strategic investments in technology platforms, commercial readiness, and partnerships position BioNTech for sustainable growth and value enhancement.
Balancing cost control, revenue generation, and clinical execution will be crucial for BioNTech to capitalize on opportunities and navigate challenges effectively.

BioNTech reports Q2 progress in oncology pipeline amid financial challenges

BioNTech's Q2 2024 earnings call highlighted progress in oncology and COVID-19 vaccines, with total revenues of EUR 129 million but a net loss of EUR 808 million. The company remains focused on advancing innovative therapies and expanding its global manufacturing capabilities.

BioNTech reports robust Q3 earnings, focuses on oncology pipeline

BioNTech's Q3 2024 performance was strong, driven by COVID-19 vaccines and oncology trials.
While facing revenue challenges in certain regions, the company remains focused on growth.
Opportunities lie in advancing oncology pipeline and demonstrating product potential.
Maintaining a strong cash position provides flexibility for future investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Will New COVID-19 Vaccines Be Needed in 2022?

BioNTech's mRNA technology and bioinformatics will be difficult for competitors to replicate.

BioNTech's Pipeline, Children's Vaccines, And Comirnaty Demand

Delta Air Lines

Goldman Sachs

J.B. Hunt Transport Services

Southwest Airlines

Moderna

Pfizer

Prologis

The indexes had been trying to turn around a steep drop to the start of the week, and finally managed on Thursday.

Best Single Trading Day in Months for Dow, Nasdaq, S&P

Is (BNTX) Outperforming Other Medical Stocks This Year?

Has BioNTech SE Sponsored (BNTX) Outpaced Other Medical Stocks This Year?

Amazon

Chipotle

Disney

Bank of America

Markets climbed higher on Thursday after lawmakers in Washington reached an agreement to extend the government's debt ceiling, preventing a shutdown.

Thursday Afternoon Analyst Upgrades and Downgrades: Amazon, Bank of America, BioNTech, Chipotle, Disney and More

Shares of Pfizer Inc. PFE, -0.71% were up 0.1% in premarket trading on Thursday after the company and BioNTech SE BNTX, -5.59% announced they submitted an application for emergency use authorization for their COVID-19 vaccine in children between the ages of 5 and 11 years old. The Food and Drug Administration will review the safety and efficacy of the vaccine before deciding whether to authorize the shot for this age group.

Pfizer, BioNTech file for FDA authorization for their COVID-19 vaccine in children

The move downward follows yet more good news from rivals.

Why BioNTech Stock Sank Today

BioNTech was among the first companies in the world to bring a viable COVID-19 vaccine to market. Over the short term, the main reason to buy BioNTech is the overwhelming success of its COVID-19 vaccine.

BioNTech: Speculating On New Potential Revolutionary Medical Breakthroughs

These vaccine stocks are now cheaper due to investors' reaction to Merck's COVID-19 pill data.

Does the Sell-Off of BioNTech and Moderna Stocks Present a Buying Opportunity?

Two doses of the Pfizer-BioNTech vaccine are 90% effective against COVID-19 hospitalisation for at least six months but only 47% effective against infection after that period, according to a new study.

Pfizer-BioNTech vaccine effectiveness wanes to 47% against COVID-19 infection after six months

The European Medicine Agency's Committee for Medicinal Products for Human Use has recommended COVID-19 booster shots from Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) for adults 18 years and older. Related:   Johnson & Johnson To Seek FDA Approval For COVID-19 Booster Shot: Report.

Pfizer/BioNTech COVID-19 Booster Shots Get Recommendation From European Medicine Agency

BioNTech (BNTX) doses the first patient in a phase II study on its mRNA cancer vaccine candidate, BNT122, in patients with colorectal cancer.

BioNTech (BNTX) Begins Dosing in mRNA Cancer Vaccine Study

NEW YORK and MAINZ, Germany, October 4 , 2021— Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion on the administration of the companies' COVID-19 vaccine as a booster dose at least six months after the second dose in individuals 18 years of age and older. The European Commission (EC) will review the CHMP recommendation and is expected to make a final decision on a variation to the Conditional Marketing Authorization in the near future. If the EC grants the variation regarding a booster dose, the decision will be immediately applicable to all 27 EU member states.

Pfizer and BioNTech Receive CHMP Positive Opinion for COVID-19 Vaccine Booster in the European Union

BioNTech SE (NASDAQ: BNTX) is continuing to trade lower Monday amid news surrounding Merck & Co Inc's (NYSE: MRK) oral COVID-19 treatment. Merck, and Ridgeback, on Friday announced its investigational oral antiviral molnupiravir reduced risk of hospitalization or death by about 50% versus the placebo for patients with mild to moderate COVID-19 in Phase 3 interim analysis.

Why BioNTech Shares Are Trading Lower Again Today

Shares in Covid-19 vaccine makers, including Moderna, Novavax and BioNTech, continued their slide lower early on Monday,

BioNTech CEO Predicts New Vaccines Will Be Needed in 2022

Current COVID-19 vaccines and booster shots may not be enough to protect against future variants of the coronavirus, Ugur Sahin told the FT.

BioNTech's CEO says the world might need new COVID-19 vaccines by mid-2022 to protect against emerging variants

BioNTech's chief executive officer Ugur Sahin told the Financial Times in an interview that COVID-19 is likely to continue mutating to the point where it can escape vaccines and immune systems.

Key Words: BioNTech CEO reportedly says a different COVID vaccine may be needed by next year

The stock price of BioNTech SE (NASDAQ: BNTX) fell by over 6% in the previous trading session. This is why it happened.

BNTX Stock Price: Why It Fell Over 6%

Merck

Merck has reported strong data from its MOVe-OUT trial of molnupiravir. Molnupiravir could be an effective and safe treatment option for COVID.

New COVID Drug Boosts Merck While Moderna And BioNTech Suffer

Novavax

Vaxart

Good news from Merck and Ridgeback caused these stocks to fall.

Why Pfizer, BioNTech, Novavax, and Vaxart Stocks Are Sinking Today

The antiviral drug could put a dent into the uptake of COVID-19 vaccines, as countries still struggle to reach herd immunity due to vaccine hesitancy.

Moderna and BioNTech plummet more than 15% following news of Merck's COVID-19 antiviral pill

BioNTech SE (NASDAQ: BNTX) has dosed the first patient with its individualized mRNA cancer vaccine BNT122 (autogene cevumeran, RO7198457) in Phase 2 clinical trial.  The trial plans to enroll about 200 patients.

BioNTech Starts Dosing In Mid-Stage Colorectal Cancer Immunotherapy Trial

MAINZ, Germany, October 1, 2021 (GLOBE NEWSWIRE) --  BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), a next generation immunotherapy company pioneering novel therapies for cancer and infectious diseases, today announced that new clinical and preclinical data will be presented in six posters and one presentation at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), being held both in person and virtually from November 10 - 14, 2021. The presentations will include new data from multiple programs across various drug classes along with first-in-human data for three programs. This is the largest data collection the company will present at a scientific meeting, showcasing BioNTech's diversified oncology pipeline. “The data we will be presenting at SITC 2021 is indicative of our continued pursuit of pathbreaking science and the development of our platform technologies that tailor anti-cancer therapies to individual patient needs,” said Özlem Türeci, M.D., Co-Founder and Chief Medical Officer at BioNTech. “We are encouraged by the considerable progress within our oncology portfolio seeing multiple programs now coming to fruition. They represent critical steps for us towards bringing cancer immunotherapy into the next generation and we are looking forward to sharing the data with the scientific community at a key conference.”   Presentation Details:

BioNTech to Present New Clinical and Preclinical Data Across Multiple Immuno-Oncology Programs at 36th SITC Annual Meeting

MAINZ, GERMANY, October 1, 2021 (GLOBE NEWSWIRE) – BioNTech SE (NASDAQ: BNTX, “BioNTech” or “the Company”), announced today that the first colorectal cancer patient has been treated with its individualized mRNA cancer vaccine BNT122 (autogene cevumeran, RO7198457) in a Phase 2 clinical trial. The trial has been initiated in the United States, Germany, Spain and Belgium. It is planned to enroll about 200 patients to evaluate the efficacy of RO7198457 (BNT122) compared to watchful waiting after surgery and chemotherapy, the current standard of care for these high-risk patients. As the second deadliest cancer worldwide, the medical need for novel therapies to treat colorectal cancer remains high.

BioNTech Expands Clinical Oncology Portfolio with First Patient Dosed in Phase 2 Trial of mRNA-based Individualized Immunotherapy BNT122 in Colorectal Cancer Patients

It's not because any of the vaccine makers reported bad news.

News for BioNTech SE Stock (BNTX)